


PHARMACEUTICAL 2022

Qualigen Therapeutics Inc. Rank 291 of 466







PHARMACEUTICAL 2022

Qualigen Therapeutics Inc. Rank 291 of 466



The relative strengths and weaknesses of Qualigen Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Qualigen Therapeutics Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 34% points. The greatest weakness of Qualigen Therapeutics Inc. is the variable Expenses, reducing the Economic Capital Ratio by 74% points.

The company's Economic Capital Ratio, given in the ranking table, is 73%, being 5.1% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	20,796
Cost of Goods Sold	0
Intangible Assets	171
Liabilities, Current	4,635
Liabilities, Non-Current	1,543
Other Assets	1,664
Other Compr. Net Income	0
Other Expenses	4,881
Other Liabilities	93
Other Net Income	4,771
Other Revenues	5,654
Property and Equipment	204
Research and Development	11,717
Selling, General and Administrative Expense	11,725

Output Variable	Value in 1000 USD
Assets	22,836
Liabilities	6,271
Expenses	28,322
Revenues	5,654
Stockholders Equity	16,565
Net Income	-17,897
Comprehensive Net Income	-17,897
Economic Capital Ratio	73%

